Weiss Multi-Strategy Advisers’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-35,211
| Closed | -$3.4M | – | 421 |
|
|
2023
Q4 | $3.4M | Buy |
35,211
+5,184
| +17% | +$497K | 0.08% | 296 |
|
|
2023
Q3 | $3.64M | Buy |
30,027
+6,943
| +30% | +$785K | 0.09% | 287 |
|
|
2023
Q2 | $2.64M | Buy |
23,084
+8,848
| +62% | +$1.14M | 0.05% | 420 |
|
|
2023
Q1 | $1.96M | Buy |
14,236
+5,799
| +69% | +$752K | 0.05% | 425 |
|
|
2022
Q4 | $1.09M | Buy |
+8,437
| New | +$978K | 0.03% | 451 |
|
|
2021
Q1 | – | Sell |
-9,768
| Closed | -$1.67M | – | 826 |
|
|
2020
Q4 | $1.67M | Sell |
9,768
-4,260
| -30% | -$631K | 0.03% | 440 |
|
|
2020
Q3 | $1.97M | Buy |
14,028
+373
| +3% | +$56.7K | 0.05% | 350 |
|
|
2020
Q2 | $2.19M | Buy |
13,655
+501
| +4% | +$68.2K | 0.06% | 320 |
|
|
2020
Q1 | $1.29M | Buy |
13,154
+4,654
| +55% | +$532K | 0.05% | 289 |
|
|
2019
Q4 | $1.1M | Buy |
8,500
+500
| +6% | +$50.5K | 0.02% | 481 |
|
|
2019
Q3 | $603K | Buy |
8,000
+3,000
| +60% | +$354K | 0.01% | 479 |
|
|
2019
Q2 | $760K | Sell |
5,000
-3,000
| -38% | -$365K | 0.02% | 398 |
|
|
2019
Q1 | $954K | Sell |
8,000
-9,500
| -54% | -$1.22M | 0.02% | 398 |
|
|
2018
Q4 | $1.91M | Sell |
17,500
-22,500
| -56% | -$2.81M | 0.08% | 229 |
|
|
2018
Q3 | $6.46M | Sell |
40,000
-23,000
| -37% | -$3.14M | 0.17% | 162 |
|
|
2018
Q2 | $8.33M | Sell |
63,000
-1,500
| -2% | -$141K | 0.2% | 141 |
|
|
2018
Q1 | $4.78M | Sell |
64,500
-45,500
| -41% | -$3.03M | 0.15% | 187 |
|
|
2017
Q4 | $6.12M | Sell |
110,000
-11,000
| -9% | -$583K | 0.16% | 163 |
|
|
2017
Q3 | $5.49M | Buy |
121,000
+71,000
| +142% | +$2.84M | 0.2% | 145 |
|
|
2017
Q2 | $1.69M | Buy |
50,000
+5,000
| +11% | +$163K | 0.07% | 317 |
|
|
2017
Q1 | $1.33M | Buy |
+45,000
| New | +$1.39M | 0.05% | 353 |
|
|
2015
Q2 | – | Sell |
-24,500
| Closed | -$325K | – | 522 |
|
|
2015
Q1 | $325K | Sell |
24,500
-500
| -2% | -$6.67K | 0.01% | 393 |
|
|
2014
Q4 | $362K | Buy |
25,000
+15,000
| +150% | +$254K | 0.01% | 357 |
|
|
2014
Q3 | $211K | Hold |
10,000
| – | – | 0.01% | 490 |
|
|
2014
Q2 | $298K | Buy |
10,000
+1,050
| +12% | +$33.2K | 0.01% | 644 |
|
|
2014
Q1 | $215K | Buy |
+8,950
| New | +$228K | ﹤0.01% | 899 |
|
|
2013
Q4 | – | Sell |
-30,000
| Closed | -$891K | – | 1103 |
|
|
2013
Q3 | $1.42M | Sell |
30,000
-10,000
| -25% | -$385K | 0.03% | 376 |
|
|
2013
Q2 | $1.52M | Buy |
+40,000
| New | +$1.43M | 0.04% | 345 |
|
Other funds holding SRPT
ACA
FCM
Weiss Multi-Strategy Advisers's SRPT Position: Q1 2024 in Review
Weiss Multi-Strategy Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 35,211 shares — an estimated $3.4M sold.
Weiss Multi-Strategy Advisers first reported a position in SRPT in Q2 2013 and held it in 28 quarters. The position peaked at $8.33M in Q2 2018. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.
- Weiss Multi-Strategy Advisers reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
- Weiss Multi-Strategy Advisers sold 35,211 Sarepta Therapeutics shares in Q1 2024, an estimated $3.4M.
- Weiss Multi-Strategy Advisers first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 28 quarters.
- Weiss Multi-Strategy Advisers's Sarepta Therapeutics position peaked at $8.33M in Q2 2018.
- 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.
Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.